C4 Therapeutics, Inc. (CCCC)
NASDAQ: CCCC · Real-Time Price · USD
4.480
+0.110 (2.52%)
Jun 1, 2026, 10:48 AM EDT - Market open
C4 Therapeutics Stock Forecast
Stock Price Forecast
According to 8 analysts polled by S&P Global, C4 Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $11.57. The average 1-year stock price forecast is 158.26% higher than the current stock price, while the lowest is $6.00 (+33.93%) and the highest is $30 (+569.64%).
Price Target: $11.57 (+158.26%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for C4 Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wells Fargo | Wells Fargo | Buy Reiterates $10 | Buy | Reiterates | $10 | +123.21% | May 13, 2026 |
| Barclays | Barclays | Buy Maintains $7 | Buy | Maintains | $7 | +56.25% | May 13, 2026 |
| TD Cowen | TD Cowen | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 12, 2026 |
Unknown Analyst Jefferies No rating | Jefferies | Buy Maintains $14 | Buy | Maintains | $14 | +212.50% | Apr 10, 2026 |
| Guggenheim | Guggenheim | Buy Reiterates $7 | Buy | Reiterates | $7 | +56.25% | Feb 27, 2026 |
Financial Forecast
Revenue This Year
23.85M
from 35.95M
Decreased by -33.64%
Revenue Next Year
21.67M
from 23.85M
Decreased by -9.16%
EPS This Year
-1.00
from -1.27
EPS Next Year
-1.03
from -1.00
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 42.0M | 31.2M | ||||||
| Avg | 23.9M | 21.7M | ||||||
| Low | 5.9M | 5.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 16.8% | 30.7% | ||||||
| Avg | -33.6% | -9.2% | ||||||
| Low | -83.6% | -75.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -0.87 | -0.75 | ||||||
| Avg | -1.00 | -1.03 | ||||||
| Low | -1.18 | -1.22 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by TipRanks. Financial forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.